Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A 18F-fluorodeoxyglucose study of a mouse model of atherosclerosis and type 2 diabetes

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The year 2020 in Atherosclerosis

“…The latter were conducted in non-diabetic Apoe − /− and Ldlr − /− mice, and the impact of DPP4 inhibition on atherosclerosis in type 2 diabetic mice was still unexplored. In the present study, Virta et al [57] clearly show that DPP4 inhibition using linagliptin does not alter the development of atherosclerosis in diabetic, hypercholesterolemic Igf2/Ldlr − /− /ApoB 100/100 mice. Histological evaluation of plaque macrophage accumulation and polarisation was also similar in linagliptin and vehicle-treated controls, as was vascular 18 F-FDG uptake between the 2 groups.…”

Atherosclerosis Burdens in Diabetes Mellitus: Assessment by PET Imaging

“…Below (and in Supplementary Material, Tables S1–S5 ) the literature is summarized according to five categories: Inflammation mechanisms and targeting (FDG only, see below) [ 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 ], Early detection and prevalence of arterial FDG or NaF uptake [ 30 , 31 , 32 , 33 , 34 , 35 ], Cardiovascular risk in DM [ 36 , 37 , 38 ], Disease progression [ 39 , 40 ], Therapy [ 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 ]. …”

“…Seven studies dealt with the carotids [ 22 , 24 , 25 , 28 , 31 , 33 , 37 ], five with the coronary arteries [ 26 , 35 , 40 , 42 , 45 ], three with the aorta [ 23 , 29 , 44 ], and three with the femoral arteries [ 32 , 38 , 43 ]. Three studies focused on the carotids and the aorta [ 41 , 46 , 49 ], two on the coronary arteries and the thoracic aorta [ 47 , 48 ], and five on several major arteries [ 27 , 30 , 34 , 36 , 39 ].…”

“…Three studies focused on the carotids and the aorta [ 41 , 46 , 49 ], two on the coronary arteries and the thoracic aorta [ 47 , 48 ], and five on several major arteries [ 27 , 30 , 34 , 36 , 39 ]. Four were animal experiments [ 23 , 26 , 29 , 44 ]. One tracer only was applied in most studies (FDG in 19, NaF in 7), one study used FDG and NaF [ 39 ], and one study used FDG and 18F-flouromethylcholine [ 29 ].…”

No pleotropic effects of linagliptin on atherosclerotic plaques: Case closed

“…In this issue of Atherosclerosis, Virta and colleagues evaluated the effects of dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin on inflammation in a murine model of atherosclerosis. The authors studied 34 Igf2/Ldlr −/− Apob100/100 mice fed a high fat diet followed by randomization to linagliptin with a high fat diet versus high fat diet alone or control [1]. All mice underwent F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging followed by sacrificing euthanasia and organ harvesting for histology.…”